Candesartan cilexetil

AU:D C09CA06(WHO) In general: ℞ (Prescription only) 1-cyclohexyloxycarbonyloxyethyl 2-ethoxy-3-[[4-[2-(2''H''-tetrazol-5-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylate 145040-37-5Y 2541 8352 DB00796Y 2444Y R85M2X0D68 D00626N CHEBI:3348Y ChEMBL1014Y DTXSID0022725 Interactive image CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5)C(=O)OC(C)OC(=O)OC6CCCCC6 InChI=1S/C33H34N6O6/c1-3-42-32-34-28-15-9-14-27(31(40)43-21(2)44-33(41)45-24-10-5-4-6-11-24)29(28)39(32)20-22-16-18-23(19-17-22)25-12-7-8-13-26(25)30-35-37-38-36-30/h7-9,12-19,21,24H,3-6,10-11,20H2,1-2H3,(H,35,36,37,38)YKey:GHOSNRCGJFBJIB-UHFFFAOYSA-NY Candesartanis anangiotensin receptor blocker(ARB) primarily used to treathigh blood pressureand congestiveheart failure. It is always administered in its inactiveprodrugform,candesartan cilexetil, which is converted to the active drug during absorption in thegastrointestinal tract. Likeolmesartan, candesartan is a cascading prodrug, a feature that influences its pharmacokinetics. It has goodbioavailabilityand is considered one of the most potentAT1receptorantagonists by weight. Its effectivemaintenance doseis also relatively low. It was patented in 1990 and approved for medical use in 1997.